Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that it has initiated a structured transaction process regarding the so-called GTX platform, consisting of therapeutic peptides based on the endogenous protein alpha-1-microglobulin (A1M), together with related intellectual property and other relevant assets (the “GTX platform”).
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the ”Company”) has today entered into a conditional agreement with shareholders who together hold approximately 91.3 percent of all outstanding shares in Disruptive Pharma Holding AB (publ) (“Disruptive Pharma”) (the “Majority Shareholders”) regarding the acquisition of their shares in Disruptive Pharma. The acquisition is intended to be carried out through a issue-in-kind, whereby the Company issues new shares (“Consideration Shares”) to the sellers in exchange for payment in the form of consideration consisting of shares in Disruptive Pharma (the ”Transaction”). Additional shareholders in Disruptive Pharma may join the agreement until the completion of the Transaction.[1] Through the Transaction, Disruptive Pharma will become a subsidiary of Guard Therapeutics. Provided that all outstanding shares in Disruptive Pharma are acquired, Disruptive Pharma’s shareholders will, following the completion of the Transaction, hold approximately 55 percent of the shares and votes in the Company, while Guard Therapeutics’ existing shareholders will hold approximately 45 percent of the shares and votes. As a result of the Transaction, the Company will change its corporate name to Disruptive Pharma AB (the Company following the completion of the Transaction is hereinafter referred to as “New Disruptive Pharma”).
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announces that Nasdaq has informed the Company that it currently does not fulfil the ongoing listing requirement regarding active operations. In accordance with applicable rules, Nasdaq may therefore delist the Company’s financial instruments on 17 June 2026, provided that the Company has not, prior thereto, communicated concrete measures for how the operational requirement will be fulfilled or, in the event that the Company intends to carry out such far reaching changes that require a new listing review, submitted a complete listing application.
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides an update regarding the strategic review that was announced in December 2025.
Guard Therapeutics (publ) today announces changes to the company’s management team, in light of the conclusion of the clinical program for the drug candidate RMC-035 and the ongoing strategic review focused on a merger or a reverse takeover (RTO).
Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) hereby provides a status update regarding the strategic review that the Company announced through a press release on 4 December 2025. The review, which includes an exploration of potential strategic alternatives, including the identification of potential counterparties for a merger or a reverse takeover (RTO), is progressing according to plan and is expected to be completed during the first quarter of 2026.
Guard Therapeutics (publ) today announced its participation as a partner in a newly funded European research consortium under the 2025 Joint Transnational Call from the European Rare Diseases Research Alliance (ERDERA), aimed at accelerating the development of therapies for rare kidney diseases.
Guard Therapeutics International AB (publ) today announces that a Nomination Committee has been appointed in accordance with previous AGM resolutions.
Guard Therapeutics (publ) (“Guard” or the “Company”) announces today that Redeye Aktiebolag (“Redeye”) has been appointed as financial advisor in connection with the strategic review announced by the Company in its press release dated 4 December 2025. The review includes an assessment of potential strategic alternatives, including the identification of possible counterparties for a merger or a reverse acquisition.
Guard Therapeutics (publ) has entered into an agreement with Redeye AB regarding the service as Certified Adviser. Redeye AB will assume the role of Certified Adviser on 8 December 2025.